Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic

First Antibody Therapy EUA

Executive Summary

Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate. 

You may also be interested in...



Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets

Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise. 

Lilly COVID-19 Neutralizing Antibody Combo’s Reduced Infusion Time Offers Advantages For Providers

US FDA's EUA allows lower doses of the two antibodies than were tested in BLAZE-1, which should extend current supply. With Amgen, Lilly hopes to manufacture 1 million doses by mid-year.

Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance

Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel